Evidence map›Paper›PMID 39941774›Full record

ArticleCancers2025

Long-Term Safety and Survival Outcomes of [

Elisabetta Perrone, Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Aleksandr Eismant, Kriti Ghai, Tanay Parkar, Aditi Mishra, Axel Heidenreich and 4 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Beyond [BMC cancer · 2026
    Pooled it
  2. Review
  3. Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. PSMA-RECAP: [Frontiers in oncology · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elisabetta PerroneCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0009-0002-8404-8206
Alessandro GiordanoInstitute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Maria Lucia CalcagniInstitute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Lucia LeccisottiInstitute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0002-6000-2898
Roberto MorettiUnità della Fisica per le Scienze della Vita, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Aleksandr EismantCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0000-0002-9750-236X
Kriti GhaiCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0009-0003-4247-6824
Tanay ParkarCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0009-0000-2285-7783
Aditi MishraCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Axel HeidenreichDepartment of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Surgery, Faculty of Medicine, University of Cologne, University Hospital Cologne, 50937 Cologne, Germany.
Ralph M WirtzInstitute of Pathology, St. Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany.
Jörg MüllerDepartment of Neurology, Vivantes Klinikum Spandau, Charité-Universitätsmedizin, 10117 Berlin, Germany.ORCID 0000-0002-2518-2715
Lukas GreifensteinCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Richard P BaumCURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0000-0003-1723-0075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to retrospectively assess the safety of [

Indexed as

Actinium-225prostate cancerPSMAPSMA Radioligand Therapy (PRLT)safetysurvivalTANDEM PRLT

Identifiers

PMID39941774
PMCPMC11816130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.